These data indicated that activation of the NF-κB signaling pathway represents a major contribution to the inflammation-induced after SARS-CoV infection and that NF-κB inhibitors are promising antivirals in infections caused by SARS-CoV and potentially other pathogenic human coronaviruses. This evidence concerns the gene NFKB1 and severe acute respiratory syndrome.